Literature DB >> 9180194

Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group.

A Imrie1, A Beveridge, W Genn, J Vizzard, D A Cooper.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) resistant to the nonnucleoside reverse transcriptase inhibitor nevirapine and to the nucleoside analogue zidovudine was transmitted from a homosexual man to his sex partner. The virus source patient had commenced combination zidovudine and nevirapine therapy 2.5 years prior to his partner's primary HIV infection. He received both therapies for 7 months, then discontinued nevirapine treatment, continuing to receive zidovudine monotherapy for a further 16 months. He had ceased zidovudine therapy 6 months before the time of his partner's seroconversion. Analysis of major and minor isolates obtained from both patients soon after onset of the recipient's primary HIV infection illness confirmed that an HIV-1 variant mutant at codons 70, 98, and 181 of the viral reverse transcriptase was transmitted. This is the first documented case of transmission of HIV-1 resistant to two antiretroviral compounds.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9180194     DOI: 10.1086/516487

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  21 in total

1.  When should we delay highly active antiretroviral therapy?

Authors:  D R Bangsberg; A Moss
Journal:  J Gen Intern Med       Date:  1999-07       Impact factor: 5.128

Review 2.  Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1.

Authors:  A D Kashuba; J R Dyer; L M Kramer; R H Raasch; J J Eron; M S Cohen
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

3.  Antiretroviral Drug Resistance in HIV-1.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-08       Impact factor: 3.725

Review 4.  Measuring adherence to highly active antiretroviral therapy: implications for research and practice.

Authors:  Thomas Kerr; John Walsh; Elisa Lloyd-Smith; Evan Wood
Journal:  Curr HIV/AIDS Rep       Date:  2005-11       Impact factor: 5.071

Review 5.  Antiviral drug resistance.

Authors:  D Pillay; M Zambon
Journal:  BMJ       Date:  1998-09-05

Review 6.  HIV drug resistance: genotypic assays and their possible applications.

Authors:  A L Ballard; P A Cane; D Pillay
Journal:  Sex Transm Infect       Date:  1998-08       Impact factor: 3.519

7.  Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA.

Authors:  K K Van Rompay; M D Miller; M L Marthas; N A Margot; P J Dailey; D R Canfield; R P Tarara; J M Cherrington; N L Aguirre; N Bischofberger; N C Pedersen
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

8.  Rapid and persistent selection of the K103N mutation as a majority quasispecies in a HIV1-patient exposed to efavirenz for three weeks: a case report and review of the literature.

Authors:  Ennio Polilli; Giustino Parruti; Luana Cosentino; Federica Sozio; Annalisa Saracino; Augusta Consorte; Gioacchino Angarano; Francesco Di Masi; Elena Mazzotta; Paolo Fazii
Journal:  J Med Case Rep       Date:  2009-09-18

9.  Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection.

Authors:  Susan J Little; Simon D W Frost; Joseph K Wong; Davey M Smith; Sergei L Kosakovsky Pond; Caroline C Ignacio; Neil T Parkin; Christos J Petropoulos; Douglas D Richman
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

10.  Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride.

Authors:  V Miller; M P de Béthune; A Kober; M Stürmer; K Hertogs; R Pauwels; P Stoffels; S Staszewski
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.